Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Entera Bio is moving closer to what could become a major shift in the treatment of osteoporosis: the first oral anabolic therapy designed to rebuild bone. The biotechnology company announced yesterday ...
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 ...
Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...
EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of ...
Kaitlin Vogel is a health journalist based in New York. Her work has appeared in a variety of publications, including Healthline, Eating Well, Parade, and more. Taking cold medication unnecessarily ...
Graves’ disease is an autoimmune condition that causes hyperthyroidism, or too much thyroid hormone. Over time, high thyroid hormone levels can harm your heart, bones, skin, and eyes. Common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results